Avalyn Pharma Inc.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled medicines to treat rare respiratory diseases, particularly pulmonary fibrosis and other interstitial lung diseases. The company's approach involves creating inhaled formulations of oral medications that deliver the drug directly to the lungs, potentially improving efficacy and reducing side effects. Its pipeline includes AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib, respectively, for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. Additionally, AP03 is a fixed-dose combination of inhaled pirfenidone and nintedanib designed to deliver dual antifibrotic mechanisms. Avalyn Pharma aims to address unmet medical needs in respiratory diseases through targeted pulmonary delivery.

Avalyn Pharma Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AVLN. The trading currency is the US Dollar (USD), as the company is based in the United States. Being listed on NasdaqGS provides the company with access to a broad investor base and liquidity. The exchange is one of the major US stock exchanges, known for listing many technology and healthcare companies.

Avalyn Pharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies, particularly in the area of respiratory diseases. The company's work involves advanced drug delivery technologies, such as inhaled formulations, to treat conditions like pulmonary fibrosis. Biotechnology companies often engage in high-risk, high-reward research, and Avalyn Pharma's clinical-stage status means it is still developing its products and has not yet commercialized them.

Avalyn Pharma Inc. is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2011 and was originally known as Genoa Pharmaceuticals, Inc. It changed its name to Avalyn Pharma Inc. in July 2017. Boston is a major hub for biotechnology and pharmaceutical research, providing access to talent, academic institutions, and a supportive ecosystem for drug development. The company's focus on rare respiratory diseases aligns with the innovative environment of the region.

Avalyn Pharma is a clinical-stage biopharmaceutical company, meaning it does not yet have approved products on the market and does not generate revenue from product sales. Its business model involves developing inhaled formulations of existing oral drugs to treat rare respiratory diseases. The pipeline includes AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib) for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, and AP03, a fixed-dose combination of both. The company aims to improve upon current treatments by delivering drugs directly to the lungs, potentially enhancing efficacy and reducing systemic side effects. Avalyn Pharma's success depends on the outcome of clinical trials and regulatory approvals.